Literature DB >> 18300283

Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms.

Liqun Yu1, Hai-Ying Shen, Joana E Coelho, Inês M Araújo, Qing-Yuan Huang, Yuan-Ji Day, Nelson Rebola, Paula M Canas, Erica Kirsten Rapp, Jarrod Ferrara, Darcie Taylor, Christa E Müller, Joel Linden, Rodrigo A Cunha, Jiang-Fan Chen.   

Abstract

OBJECTIVE: To investigate whether the motor and neuroprotective effects of adenosine A(2A) receptor (A(2A)R) antagonists are mediated by distinct cell types in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson's disease.
METHODS: We used the forebrain A(2A)R knock-out mice coupled with flow cytometric analyses and intracerebroventricular injection to determine the contribution of A(2A)Rs in forebrain neurons and glial cells to A(2A)R antagonist-mediated motor and neuroprotective effects.
RESULTS: The selective deletion of A(2A)Rs in forebrain neurons abolished the motor stimulant effects of the A(2A)R antagonist KW-6002 but did not affect acute MPTP neurotoxicity. Intracerebroventricular administration of KW-6002 into forebrain A(2A)R knock-out mice reinstated protection against acute MPTP-induced dopaminergic neurotoxicity and attenuated MPTP-induced striatal microglial and astroglial activation.
INTERPRETATION: A(2A)R activity in forebrain neurons is critical to the control of motor activity, whereas brain cells other than forebrain neurons (likely glial cells) are important components for protection against acute MPTP toxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18300283     DOI: 10.1002/ana.21313

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  63 in total

Review 1.  Xanthines as adenosine receptor antagonists.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2011

2.  Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease.

Authors:  Patricia K Sonsalla; Lai-Yoong Wong; Suzan L Harris; Jason R Richardson; Ida Khobahy; Wenhao Li; Bharathi S Gadad; Dwight C German
Journal:  Exp Neurol       Date:  2012-01-28       Impact factor: 5.330

Review 3.  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

Authors:  Marie Therese Armentero; Annalisa Pinna; Sergi Ferré; José Luis Lanciego; Christa E Müller; Rafael Franco
Journal:  Pharmacol Ther       Date:  2011-07-23       Impact factor: 12.310

4.  Intracellular acidification causes adenosine release during states of hyperexcitability in the hippocampus.

Authors:  Chris G Dulla; Bruno G Frenguelli; Kevin J Staley; Susan A Masino
Journal:  J Neurophysiol       Date:  2009-07-22       Impact factor: 2.714

5.  Selective inactivation of adenosine A(2A) receptors in striatal neurons enhances working memory and reversal learning.

Authors:  Catherine J Wei; Philipp Singer; Joana Coelho; Detlev Boison; Joram Feldon; Benjamin K Yee; Jiang-Fan Chen
Journal:  Learn Mem       Date:  2011-06-21       Impact factor: 2.460

Review 6.  Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy.

Authors:  Detlev Boison; Philipp Singer; Hai-Ying Shen; Joram Feldon; Benjamin K Yee
Journal:  Neuropharmacology       Date:  2011-02-17       Impact factor: 5.250

7.  Homocysteine and A2A-D2 Receptor-Receptor Interaction at Striatal Astrocyte Processes.

Authors:  Chiara Cervetto; Arianna Venturini; Diego Guidolin; Guido Maura; Mario Passalacqua; Carlo Tacchetti; Pietro Cortelli; Susanna Genedani; Simona Candiani; Paola Ramoino; Simone Pelassa; Manuela Marcoli; Luigi F Agnati
Journal:  J Mol Neurosci       Date:  2018-07-20       Impact factor: 3.444

8.  Systemic inflammation regulates microglial responses to tissue damage in vivo.

Authors:  Stefka Gyoneva; Dimitrios Davalos; Dipankar Biswas; Sharon A Swanger; Ethel Garnier-Amblard; Francis Loth; Katerina Akassoglou; Stephen F Traynelis
Journal:  Glia       Date:  2014-05-07       Impact factor: 7.452

Review 9.  Adenosine receptors as drug targets--what are the challenges?

Authors:  Jiang-Fan Chen; Holger K Eltzschig; Bertil B Fredholm
Journal:  Nat Rev Drug Discov       Date:  2013-04       Impact factor: 84.694

10.  Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease.

Authors:  Xavier Guitart; Jordi Bonaventura; William Rea; Marco Orrú; Lucrezia Cellai; Ilaria Dettori; Felicita Pedata; Marc Brugarolas; Antonio Cortés; Vicent Casadó; Ching-Pang Chang; Manikandan Narayanan; Yijuang Chern; Sergi Ferré
Journal:  Neurobiol Dis       Date:  2016-08-24       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.